Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis-Reference-Cited by-同舟云学术

Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis

Published:2022-01 Issue:1 Volume:17 Page:103-115
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Planchard David,Besse Benjamin,Groen Harry J.M.,Hashemi Sayed M.S.,Mazieres Julien,Kim Tae Min,Quoix Elisabeth,Souquet Pierre-Jean,Barlesi Fabrice,Baik Christina,Villaruz Liza C.,Kelly Ronan J.,Zhang Shirong,Tan Monique,Gasal Eduard,Santarpia Libero,Johnson Bruce E.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference46 articles.

1. National Comprehensive Cancer Network. Non-small cell lung cancer, version 6. 2020. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed June 29, 2020.

2. Non-small cell lung cancer: current treatment and future advances;Zappa;Transl Lung Cancer Res,2016

3. Personalized diagnostic workflows: the next wave of precision medicine in NSCLC;Dagogo-Jack;J Thorac Oncol,2020

4. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review;Arbour;JAMA,2019

5. Clinical outcomes after whole-genome sequencing in patients with metastatic non-small-cell lung cancer;Tsang;Cold Spring Harb Mol Case Stud,2019

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of chemo-immunotherapy in metastatic BRAF-mutated lung cancer: a single-center retrospective data;Frontiers in Oncology;2024-01-31

2. BRAF — a tumour-agnostic drug target with lineage-specific dependencies;Nature Reviews Clinical Oncology;2024-01-26

3. Molecular Targeting of the BRAF Proto-Oncogene/Mitogen-Activated Protein Kinase (MAPK) Pathway across Cancers;International Journal of Molecular Sciences;2024-01-03

4. Path Less Traveled: Targeting Rare Driver Oncogenes in Non–Small-Cell Lung Cancer;JCO Oncology Practice;2024-01

5. Comprehensive Genomic Analysis of Patients With Non–Small-Cell Lung Cancer Using Blood-Based Circulating Tumor DNA Assay: Findings From the BFAST Database of a Single Center in Taiwan;JCO Precision Oncology;2024-01